Conexeu Sciences Inc.
No SEC Form 4 filings for $CNXU in the last 30 days.
IPO Edge hosted a 30-minute fireside chat with Conexeu Sciences (Nasdaq: CNXU) CEO Miles Harrison. The preclinical regenerative tissue company discussed its ECM platform for wound care, aesthetics, oral health, and veterinary uses, including a bioresorbable scaffold for breast implants. It cited an anticipated FDA 510(k) submission in early 2027 and related catalysts.
Conexeu Sciences Inc. (NASDAQ: CNXU) says its investigational CXU tissue-restoration platform targets large-volume injectable aesthetics, aiming to restore body volume after GLP-1 weight loss. The company completed a 12-month P.R.O.O.F. preclinical study in a large-volume model, with results not yet peer-reviewed. Boston Consulting Group projects GLP-1-related aesthetic provider revenue could rise to about $2.0B by 2030.
Conexeu Sciences Inc. (Nasdaq: CNXU) says its preclinical CXU tissue-restoration platform targets large-volume body contouring needs created by GLP-1 weight loss. The company completed a 12-month P.R.O.O.F. preclinical study in small and large-volume models. Boston Consulting Group projects GLP-1-related aesthetic care revenue rising from about $0.7B to $2.0B by 2030.
Over the past 7 days, alphai's AI scored 1 news story mentioning CNXU (Conexeu Sciences Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent CNXU coverage spans technology and insider activity.
The article is a promotional fireside chat but adds a specific regulatory timeline (early 2027 510(k)) and outlines near-term program catalysts that can shift investor expectations.
The article is a preclinical milestone update tied to a potential new injectable aesthetics category, but it does not include regulatory clearance or peer-reviewed results.
Preclinical milestone completion supports the narrative of platform progress, but it is not a regulatory or commercial catalyst.
Preclinical evidence completion and a stated regulatory timeline can improve perceived de-risking, but it is not a clinical readout or clearance.
Milestone completion supports the company’s regulatory timeline toward a predicate-based 510(k), but it is still preclinical and non-peer-reviewed.
alphai scores every news story that mentions CNXU with an AI model for sentiment and relevance, and aggregates insider trades from Conexeu Sciences Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
IPO Edge hosted a 30-minute fireside chat with Conexeu Sciences (Nasdaq: CNXU) CEO Miles Harrison. The preclinical regenerative tissue company discussed its ECM platform for wound care, aesthetics, oral health, and veterinary uses, including a bioresorbable scaffold for breast implants. It cited an anticipated FDA 510(k) submission in early 2027 and related catalysts.
4 min readConexeu Sciences Inc. (NASDAQ: CNXU) says its investigational CXU tissue-restoration platform targets large-volume injectable aesthetics, aiming to restore body volume after GLP-1 weight loss. The company completed a 12-month P.R.O.O.F. preclinical study in a large-volume model, with results not yet peer-reviewed. Boston Consulting Group projects GLP-1-related aesthetic provider revenue could rise to about $2.0B by 2030.
5 min readConexeu Sciences Inc. (Nasdaq: CNXU) says its preclinical CXU tissue-restoration platform targets large-volume body contouring needs created by GLP-1 weight loss. The company completed a 12-month P.R.O.O.F. preclinical study in small and large-volume models. Boston Consulting Group projects GLP-1-related aesthetic care revenue rising from about $0.7B to $2.0B by 2030.
5 min readConexeu Sciences Inc. (Nasdaq: CNXU) says it has completed a 12-month preclinical P.R.O.O.F. study for its CXU tissue-restoration scaffold, aimed at large-volume injectable aesthetics. The company cites growing aesthetics markets and GLP-1-driven demand, and targets a 510(k) submission in Q1 2027, pending further testing.
6 min readConexeu Sciences Inc. (NASDAQ: CNXU) says it completed its 12-month P.R.O.O.F preclinical phase for its CXU regenerative tissue platform, meeting objectives across facial, body, and mechanical performance pillars. The company plans a predicate-based 510(k) submission for its lead Ten-Minute Tissue device in Q1 2027, targeting faster review, subject to required testing and FDA review.
4 min readConexeu Sciences (CNXU) said its 12-month P.R.O.O.F study for its CXU tissue-restoration platform met tissue restoration objectives in facial models and performance benchmarks for injectability and volumizing capacity. The company plans a predicate-based 510(k) wound-care path with a Q1 2027 submission and aims to use clearance to expand into medical aesthetics. Stock closed at $9.49.
4 min readConexeu Sciences Inc. (NASDAQ: CNXU) says it completed the P.R.O.O.F preclinical phase of its CXU program, which it frames as an evidence base for a first move into medical aesthetics injectables. The company targets a predicate-based FDA 510(k) submission in Q1 2027. It cites a $11B aesthetics injectable market and GLP-1 growth projections.
4 min readConexeu Sciences Inc. (Nasdaq: CNXU) said it completed its 12-month P.R.O.O.F preclinical study for its CXU™ flowable collagen platform, meeting tissue-restoration objectives in small- and large-volume models and injectable performance benchmarks (injectability and volumizing). The company plans a predicate-based 510(k) for wound care in Q1 2027 as a first regulatory step toward medical aesthetics.
5 min readConexeu Sciences Inc. (NASDAQ: CNXU) opened a new R&D facility at adMare BioInnovations’ M4 Innovation Centre (ribbon-cutting June 23, 2026), expanding its CXU™ regenerative tissue platform. The company targets aesthetics and body contouring tied to GLP-1 demand, estimating a ~$2B market by 2030 and planning a 510(k) in early 2027.
4 min readPurcell Lynn Sebastian purchased 202,500 indirectly-held shares of Conexeu Sciences Inc. (CNXU) at $0.80 ($0.16M total) on 2026-06-18.
2 min read
